Avi Hayun-36


Cell Cure Neurosciences’ shareholders include:

Cell Cure announced a $7.1 million equity investment by BioTime, Hadasit Bio-Holdings and Teva on October 10, 2010. In addition,  Cell Cure Neurosciences entered into an exclusive license option agreement with Teva Pharmacueticals for the development of the company’s OpRegen™ cell therapy product for advanced macular degeneration.

BioTime, Inc. and its subsidiary, ES Cell International Ltd. (ESI), are majority shareholders in Cell Cure. Cell Cure is BioTime’s neurological arm for advancing human embryonic stem cell based therapies.  Cell Cure also enjoys non-dilutive financial support from the Office of the Chief Scientist in Israel’s Ministry of Industry, Trade and Labor, which funds up to 60% of approved annual R&D programs.